Related references
Note: Only part of the references are listed.Regulatory T Cells Require Mammalian Target of Rapamycin Signaling To Maintain Both Homeostasis and Alloantigen-Driven Proliferation in Lymphocyte-Replete Mice
Ying Wang et al.
JOURNAL OF IMMUNOLOGY (2011)
T regulatory cells and the control of alloimmunity: from characterisation to clinical application
Joanna Wieckiewicz et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Michael Dandel et al.
CURRENT VASCULAR PHARMACOLOGY (2010)
An Oscillatory Switch in mTOR Kinase Activity Sets Regulatory T Cell Responsiveness
Claudio Procaccini et al.
IMMUNITY (2010)
The Pim Kinase Pathway Contributes to Survival Signaling in Primed CD8+ T Cells upon CD27 Costimulation
Victor Peperzak et al.
JOURNAL OF IMMUNOLOGY (2010)
In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells
Satish N. Nadig et al.
NATURE MEDICINE (2010)
Ex Vivo-Expanded Human Regulatory T Cells Prevent the Rejection of Skin Allografts in a Humanized Mouse Model
Fadi Issa et al.
TRANSPLANTATION (2010)
Number of Peripheral Blood Regulatory T Cells and Lymphocyte Activation at 3 Months After Conversion to mTOR Inhibitor Therapy
D. San Segundo et al.
TRANSPLANTATION PROCEEDINGS (2010)
Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning
James L. Riley et al.
IMMUNITY (2009)
mTOR signaling at a glance
Mathieu Laplante et al.
JOURNAL OF CELL SCIENCE (2009)
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Nancy Lee et al.
BMC Pharmacology & Toxicology (2009)
The functional plasticity of T cell subsets
Jeffrey A. Bluestone et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Effect of rapamycin therapy on coronary artery physiology early after cardiac transplantation
Seema S. Sinha et al.
AMERICAN HEART JOURNAL (2008)
Cardiac allograft vasculopathy - Recent developments
Daniel Schmauss et al.
CIRCULATION (2008)
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
Sokol Haxhinasto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin
Samik Basu et al.
JOURNAL OF IMMUNOLOGY (2008)
Regulatory CD4 T cells: sensing the environment
Giuseppe Matarese et al.
TRENDS IN IMMUNOLOGY (2008)
Differential impact of mammalian target of rapamycin inhibition on CD4(+)CD25(+)Foxp3(+) regulatory T cells compared with conventional CD4(+) T cells
Robert Zeiser et al.
BLOOD (2008)
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury
Piero Ruggenenti et al.
TRANSPLANTATION (2007)
Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult heart transplant report - 2007
David O. Taylor et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans
Maria-Grazia Roncarolo et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Regulatory T cells and T cell depletion: Role of immunosuppressive drugs
Marina Noris et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients
Manuela Battaglia et al.
JOURNAL OF IMMUNOLOGY (2006)
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
Robert Zeiser et al.
BLOOD (2006)
Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferon-γ
T Yi et al.
TRANSPLANTATION (2006)
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
M Battaglia et al.
BLOOD (2005)
The generation of CD25+CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen
A Bushell et al.
JOURNAL OF IMMUNOLOGY (2005)
The Pim kinases control rapamycin-resistant T cell survival and activation
CJ Fox et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets
G Kwon et al.
DIABETES (2004)
Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years - A randomized clinical trial
A Keogh et al.
CIRCULATION (2004)
Use of rapamycin slows progression of cardiac transplantation vasculopathy
D Mancini et al.
CIRCULATION (2003)
Regulatory T cells in transplantation tolerance
KJ Wood et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression
PN Ruygrok et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2003)